Since previous data from our group demonstrated a synergistic anticancer effect of parenteral IFN-I and some anticancer drugs, such as cyclophosphamide (CTX), cis-diamminedichloroplatinum (II) (CDDP) and epigenetic compounds [29,46,50,51], we aimed to evaluate whether Sl-IFN is also effective when combined with these drugs in tumor-bearing mice. Here, IFNA1 is linked to neoplasm.